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Objectives: To report on survival from a large multicenter cohort of neonates with hypoplastic left heart syndrome requiring extracorporeal membrane oxygenation-assisted cardiopulmonary resuscitation after stage 1 palliation operation. Design: Retrospective analysis of data from the Extracorporeal Life Support Organization data registry (1998 through 2013). We computed the survival to hospital discharge for neonates (age < 30 d) who required extracorporeal membrane oxygenation after stage 1 palliation and evaluated factors associated with mortality using multivariate logistic regression analysis. Setting: Multicenter data reported to Extracorporeal Life Support Organization registry. Patients: Infants with hypoplastic left heart syndrome after stage 1 palliation who received extracorporeal membrane oxygenationassisted cardiopulmonary resuscitation. Interventions: None. Measurements and Main Results: There were 307 extracorporeal membrane oxygenation runs in the setting of extracorporeal membrane oxygenation-assisted cardiopulmonary resuscitation in 293 neonates with hypoplastic left heart syndrome following stage 1 palliation operation. The median age at cannulation was 9 days (interquartile range, 5-14 d). Survival to hospital discharge was 36%. In univariate analysis, gestational age, weight, extracorporeal membrane oxygenation duration, presence of air embolism, hemorrhagic complications, renal failure, and pulmonary complications (pulmonary hemorrhage and pneumothorax) were all associated with nonsurvival. In multivariate analysis, lower body weight at cannulation (odds ratio, 3.9; 95% CI, 1.9-8.3), duration of the extracorporeal membrane oxygenation (odds ratio, 3.4; 95% CI, 1.9-7.3), and renal failure while on extracorporeal membrane oxygenation (odds ratio, 2; 95% CI, 1.2-3.5) increased odds of mortality. Conclusions: Mortality for neonates with hypoplastic left heart syndrome supported with extracorporeal membrane oxygenationassisted cardiopulmonary resuscitation after stage 1 palliation is high. Lower body weight, increased duration of extracorporeal membrane oxygenation support, and renal failure increased mortality. (Pediatr Crit Care Med 2014; 15:538-545) Key Words: cardiopulmonary resuscitation; extracorporeal membrane oxygenation; extracorporeal membrane oxygenationassisted cardiopulmonary resuscitation; hypoplastic left heart syndrome; Norwood operation H emodynamic instability and cardiac arrest are common in the postoperative period in neonates undergoing stage 1 palliation (S1P) operation for hypoplastic left heart syndrome (HLHS). Return of spontaneous circulation following conventional cardiopulmonary resuscitation (CPR) for cardiac arrest in these patients is often not achieved (1) . Extracorporeal membrane oxygenation (ECMO) is commonly used to provide circulatory support as an extension of conventional CPR (ECPR) therapies in these patients (2) . Previous reports describing outcomes following ECPR in children with congenital heart disease have shown that patients with single-ventricle lesions are at increased risk of death following ECPR. However, these studies include a broad range of single-ventricle lesions including single-ventricle patients palliated with systemic to pulmonary artery shunts and cavopulmonary connections. Thus, generalizing these findings to children with HLHS undergoing S1P may be difficult. Current single-center reports of survival following ECPR in HLHS patients following S1P report variable survival outcomes (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Because cardiac arrest and use of ECPR in neonates with HLHS undergoing S1P is commonplace and maintaining an ECPR program is expensive, improving our understanding of potential benefits, namely survival to discharge, morbidity, and long-term outcomes in this population, is critical.
The purpose of this study was to describe the survival to hospital discharge and factors associated with mortality for neonates with HLHS supported with ECPR after undergoing S1P using data from the Extracorporeal Life Support Organization's (ELSO) database.
METHODS

Data Source and Study Population
We retrospectively analyzed data obtained from the ELSO Registry for neonates with HLHS who underwent ECPR after S1P. The registry collects data on ECMO use from patients of all ages from 230 U.S. and international centers. Participating centers voluntarily report data to the registry using a standardized data form. Data reported include demographic, procedural information, pre-ECMO status, ECMO support details, complications, and outcomes. Data are reported to ELSO after approval from the local institutional review board at each center. The data user agreement between ELSO and member centers allows the release of limited de-identified data for research. The Committee on Clinical Investigation at Children's Hospital Boston approved use of de-identified data from ELSO for purposes of this study.
The study population included all neonates (≤ 30 d) with HLHS supported with ECMO following cardiac arrest after S1P and reported to the ELSO Registry from 1998 to 2013. A primary admission diagnosis of HLHS (International Classification of Diseases, 9th revision, code 746.7) and a procedure code for S1P (Common Procedural Terminology Codes 33619) were used to identify these patients. The registry does not collect information of the anatomical variants of HLHS and surgical details including S1P shunt types.
Data Categorization
Venoarterial ECMO was used in all subjects. Arterial cannulation sites were categorized as aorta, common carotid artery, or other. Venous cannulation sites were grouped into right atrium, internal jugular vein, or other. Transthoracic cannulation was distinguished from peripheral cannulation by cannulation site. The duration of mechanical ventilation before ECPR was the cumulative duration of mechanical ventilation from endotracheal intubation to ECMO deployment and included mechanical ventilatory support in the pre-and postoperative periods prior to ECMO deployment. ECMO complications were categorized using complications codes developed by the ELSO registry for purposes of data reporting using previously established methodology (13) .
Statistical Analysis
Survival was defined as survival to discharge from the ECMO center to home or to another facility. The demographic, pre-ECMO, ECMO support, and complication data were compared between survivors and nonsurvivors. The MannWhitney U test or Wilcoxon test was used to compare continuous data, and the chi-square test was used for categorical data. Fisher exact test was used when the expected counts in more than 20% of cells was less than 5. The data are presented as median with interquartile ranges (IQRs, 25th to 75th percentile) or frequencies with percentages, unless specified otherwise. For patients with multiple ECMO runs (n = 14), only data from the first run were analyzed. A p value less than or equal to 0.05 was considered statistically significant.
Using multivariate logistic regression modeling we explored the patient and ECMO support factors associated with mortality. Candidate variables for inclusion in the multivariable model were selected from the bivariate analysis based on p values of less than or equal to 0.1 and entered into the regression model using a stepwise selection process. Variables were retained if their adjusted p value was less than or equal to 0.1. A continuous variable retained in a model was evaluated for a linear association with mortality and only retained as a continuous variable if this assumption was satisfied. Variables not meeting criteria for linearity were divided according to their distribution and refitted into the model as categorical variables. The data were analyzed with SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
Study Population
A total of 293 neonates with HLHS underwent 307 ECPR runs after S1P during 1998 through 2013. The number of ECPR events per year and survival, as well as trends relative to all neonatal cardiac ECMO (age < 30 d), are shown in Figure 1 . The median age at ECPR was 9 days (IQR, 5-14 d), median weight was 3 kg (IQR, 2.7-3.4 kg), and gestational age 38 weeks (IQR, 37-39 wk). Median time from admission to ECMO was 180 hours (94-310 hr). Overall, 106 of 293 patients (36%) undergoing ECPR survived to hospital discharge. Of the 14 patients who required more than one ECPR run, there were only two survivors. ECMO was used as a bridge to transplant in four patients supported with ECPR, with two surviving to discharge.
ECMO Survivors Versus Nonsurvivors
Demographic and Pre-ECPR Status. The demographic and pre-ECMO features of survivors and nonsurvivors are shown in Table 1 . In univariate analysis, lower gestational age, younger age at the time of cannulation, and lower body weight at the time of ECMO cannulation were all associated with nonsurvival. Duration of mechanical ventilation prior to ECPR, arterial blood gas pH, and Pao 2 in arterial blood prior to ECMO were not significantly associated with nonsurvival.
ECMO Support and Complications. ECMO support and complications in survivors and nonsurvivors are shown in Table 2 . In univariate analysis, occurrence of air embolism, hemorrhagic complications, surgical bleeding, renal failure, pulmonary complications (pulmonary hemorrhage or pneumothorax), and duration of ECMO were all associated with nonsurvival. ECMO flow and site of cannulation (peripheral vs transthoracic) were not significantly associated with nonsurvival. Factors Associated With Mortality. Two multivariate regression models of factors associated with mortality are shown in Table 3 . In model 1, we evaluated the demographic, pre-ECMO, and ECMO variables. Lower body weight at the time of ECMO was independently associated with increased odds of mortality. Patients with body weight less than 2.6 kg and 2.6-3.3 kg had increased odds of mortality compared with those greater than 3.3 kg (p = 0.01). In a second regression model (model 2), we explored the association of ECMO complications and mortality. After adjusting for the duration of ECMO support, renal failure during ECMO was independently associated with increased odds of mortality (p = 0.01). Longer ECMO duration was also significantly associated with higher odds of mortality. The odds of mortality was significantly higher in those whose ECMO runs were greater than 96 hours (third and fourth quartiles of the distribution of ECMO duration) compared with those whose runs ended less than 52 hours (first quartile).
Distribution of Survivors and Nonsurvivors Based on ECMO Duration. ECMO survival to hospital discharge stratified by day of ECMO is shown in Figure 2 . There were very few survivors after 9 days of ECMO support.
DISCUSSION
Survival to discharge of 36% for ECPR in neonates with HLHS following S1P is poor but higher than the 31% survival reported by Sherwin et al (13) for ECMO use in all patients with HLHS supported with ECMO following S1P including those supported electively. However, survival for ECPR in HLHS patients is generally lower than the 40-55% ECPR survival reported for cardiac patients with a broad range of diagnosis and including postoperative and nonoperative patients (7, 9, 14, 15) . The decreased survival outcomes for ECMO in HLHS neonates following S1P may reflect patient and ECMO management challenges specific to this population. First, there is a continued need to balance pulmonary and systemic blood flow even after ECMO deployment. Second, residual anatomical issues such as tricuspid valve regurgitation, coronary insufficiency from small ascending aorta, coronary obstruction from reconstruction of the ascending aorta, or aortic arch obstruction can be present and may require investigation using cardiac catheterization and surgical correction during ECMO to allow successful decannulation from ECMO. Finally, myocardial injury acquired during cardiopulmonary bypass and S1P may not always be reversible. The occurrence of cardiac arrest in this population may cause additional end-organ and neurological injury, and these issues may not be improved even with ECMO support. Thus, we were surprised to find that the survival following ECPR was similar to patients supported more electively in this population, and given that return of spontaneous circulation following CPR is not reliably achieved in ECPR may be appropriate support in some circumstances following S1P operation for neonates with HLHS (1).
There has been a suggestion that earlier and elective ECMO prior to onset of cardiac arrest may be beneficial, potentially avoiding the morbidity associated with CPR in this population. Hoskote et al (16) , in a series of 25 patients with single-ventricle physiology supported with ECMO, showed that early use of ECMO electively prior to the onset of multiple organ failure and cardiac arrest improved short-and long-term outcomes. Neonates with progressive myocardial failure after S1P may acquire increasing end-organ injury that may be worsened or rendered irreversible following cardiac arrest. Thus, late ECMO support in S1P neonates after the onset of end-organ dysfunction may not be successful. Ungerleider et al (17) demonstrated preemptive use of ECMO initiated in the operating room after weaning off cardiopulmonary bypass was safe and feasible, with 89% survival to hospital discharge in 18 infants with HLHS undergoing S1P supported prophylactically with ECMO in the postoperative period. Although elective initiation of ECMO prior to the onset of end-organ injury or CPR is intuitive, our results do not seem to support this assertion. In previous studies, pre-ECMO inotropic use was significantly associated with increased mortality (5, 13) . In our analysis, this was not significantly associated with mortality (p = 0.07 in univariate and multivariable models). Since the majority of patients considered for ECMO following S1P would be on some inotropic support, the need for inotropes alone is not a particularly useful distinction. Dosing and type of inotropes needed to maintain cardiac function may serve as adjuncts to vital signs and laboratory information in deciding the need and timing of ECMO support, but these were unfortunately not available in the database for analysis. The strongest predictor of outcome in our multivariate analysis was body weight at the time of ECMO cannulation. Neonates weighing greater than 3.3 kg were approximately four times more likely to survive ECPR than those less than 2.6 kg. Birth weight less than 2.5 kg has been shown to be a risk factor for mortality in neonates with HLHS undergoing S1P (18, 19) . Birth weight and gestational age have been shown to be risk factors for neonates undergoing cardiac surgery with poorer outcomes reported for low birth weight (LBW) and premature infants (19) (20) (21) . Similarly, body weight has shown to be a predictor of survival to hospital discharge in some but not all prior studies of neonates supported by ECMO after cardiac surgery (3, 4, 9, 13, 16, 22) . Both LBW and lower gestational age have been shown to be risk factors for CNS injury during ECMO (18) . There is no clear dividing line, but the four-fold difference in survival based on weight may help guide risk stratification for use of ECMO in this particularly vulnerable population.
Morris et al (22) and Sherwin et al (13) demonstrated that prolonged mechanical ventilation prior to ECMO increased odds of mortality following ECMO support, but this did not prove significant in our analysis. Once on ECMO, outcomes were better in patients with shorter ECMO duration, consistent with prior reports (3, 13, 16) . Thus, prompt diagnosis and management of the etiology of cardiac arrest while on ECMO are essential. Although surgical intervention during ECMO can increase the risk of bleeding complications, other studies have shown that prompt correction of residual anatomical cardiac lesions may be beneficial and can help reduce ECMO duration and improve survival (23, 24) . Further, Allan et al (4) showed that in neonates undergoing shunted single-ventricle palliation supported with ECMO, survival to discharge was significantly higher in those supported with ECMO in the setting of an acutely reversible event such as systemic to pulmonary artery shunt occlusion resulting in cardiac arrest, rather than those supported with ECMO for progressive myocardial failure. Thus, patients with a reversible cause of cardiac arrest such as acute systemic to pulmonary artery shunt obstruction seem to be best suited to support with ECPR.
In the largest series of all ECMO in HLHS following S1P, there were few survivors after 9 days, similar to our findings here for ECPR (13) . A patient failing to wean off ECMO within 9 days could be considered for cardiac transplantation. Given the long wait times for donor grafts and no reliable options for durable mechanical circulatory support in this population, successful bridge to transplantation on further ECMO support may be difficult to achieve (25) . Given these obstacles, inability to wean off ECMO after 9 days of support can be used to provide families prognostic information to aid in making decisions regarding further care. Our results are limited by the retrospective design and use of a multicenter database. Data reported to ELSO are not specific for studying ECPR in patients with HLHS undergoing S1P. For example, data on type of shunt used for S1P, support times for cardiac surgery, presence or absence of residual abnormalities, and CPR duration and management were not recorded. Thus, important prognostic factors may not be represented in the data. Furthermore, data on reporting center demographics and practice variability among centers regarding the use and the treatment of patient on ECMO were not available for analysis. Important information on long-term survival and neurological and functional outcomes were not available to help adequately assess the usefulness of ECPR in this high-risk cohort.
CONCLUSIONS
ECPR is increasingly used to support patients with HLHS after S1P. Mortality for neonates with HLHS supported with ECPR after S1P palliation is high. Lower body weight, renal failure, and longer ECMO duration increased odds of mortality. Survival beyond 9 days of ECMO support is poor and should prompt exploration of treatment options with the family.
